Mia J. Biondi

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Correction: Reimbursement restrictions reduce liver fibrosis screening in adults with diabetes in Ontario: a population-based interrupted time series analysis.

Correction: Reimbursement restrictions reduce liver fibrosis screening in adults with diabetes in Ontario: a population-based interrupted time series analysis.

Journal: Scientific reports

Published: August 04, 2026

A 40-year-old man with a new diagnosis of hepatitis B.

A 40-year-old man with a new diagnosis of hepatitis B.

Journal: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

Published: July 13, 2026

Correction: Scaling up point-of-care hepatitis C testing in Canada: protocol for a multilevel implementation science study of clinical processes, barriers, facilitators and implementation strategies (SCALE-POCT study).

Correction: Scaling up point-of-care hepatitis C testing in Canada: protocol for a multilevel implementation science study of clinical processes, barriers, facilitators and implementation strategies (SCALE-POCT study).

Journal: Implementation science communications

Published: June 18, 2026

HIV post-exposure prophylaxis (PEP) and PEP-in-pocket (PIP) for women: A rodgers' evolutionary concept analysis.

HIV post-exposure prophylaxis (PEP) and PEP-in-pocket (PIP) for women: A rodgers' evolutionary concept analysis.

Journal: Women's health (London, England)

Published: June 02, 2026

An Update on HIV Pre-Exposure Prophylaxis (PrEP) Among Women.

An Update on HIV Pre-Exposure Prophylaxis (PrEP) Among Women.

Journal: Viruses

Published: April 29, 2026

DAAs in pregnancy are the only potential intervention to decrease vertical transmission: Pregnancy DAA data support safety.

DAAs in pregnancy are the only potential intervention to decrease vertical transmission: Pregnancy DAA data support safety.

Journal: Hepatology communications

Published: February 05, 2026

A Gender-Based Descriptive Analysis of the Canadian Network Undertaking Against Hepatitis C (CANUHC) Cohort From 2015-2023.

A Gender-Based Descriptive Analysis of the Canadian Network Undertaking Against Hepatitis C (CANUHC) Cohort From 2015-2023.

Journal: Open forum infectious diseases

Published: December 17, 2025

Reimbursement restrictions reduce liver fibrosis screening in adults with diabetes in Ontario: a population-based interrupted time series analysis.

Reimbursement restrictions reduce liver fibrosis screening in adults with diabetes in Ontario: a population-based interrupted time series analysis.

Journal: Scientific reports

Published: December 12, 2025

Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening Program.

Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening Program.

Journal: Open forum infectious diseases

Published: November 09, 2025

Scaling up point-of-care hepatitis C testing in Canada: protocol for a multilevel implementation science study of clinical processes, barriers, facilitators and implementation strategies (SCALE-POCT study).

Scaling up point-of-care hepatitis C testing in Canada: protocol for a multilevel implementation science study of clinical processes, barriers, facilitators and implementation strategies (SCALE-POCT study).

Journal: Implementation science communications

Published: October 08, 2025

National hepatitis B and C estimates for 2021: Measuring Canada's progress towards eliminating viral hepatitis as a public health concern.

National hepatitis B and C estimates for 2021: Measuring Canada's progress towards eliminating viral hepatitis as a public health concern.

Journal: Canada communicable disease report = Releve des maladies transmissibles au Canada

Published: August 27, 2025

Peginterferon λ for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trial.

Peginterferon λ for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trial.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: June 25, 2025

Showing 1-12 of 70

Last Updated: 09/26/2026